Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
28.44
+1.12 (4.10%)
At close: Aug 1, 2025, 4:00 PM
28.24
-0.20 (-0.69%)
After-hours: Aug 1, 2025, 7:50 PM EDT
Six Flags Entertainment Revenue
Ultragenyx Pharmaceutical had revenue of $139.29M in the quarter ending March 31, 2025, with 27.99% growth. This brings the company's revenue in the last twelve months to $590.69M, up 33.46% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$590.69M
Revenue Growth
+33.46%
P/S Ratio
4.50
Revenue / Employee
$456,483
Employees
1,294
Market Cap
2.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
| Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RARE News
- 3 days ago - Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 4 days ago - Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst - Seeking Alpha
- 5 days ago - Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks - Benzinga
- 15 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 19 days ago - Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 22 days ago - US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - Reuters
- 22 days ago - Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - GlobeNewsWire